Table 1 Demographics and Characteristics, History of At-Risk Behaviors, PrEP Awareness and Preferences of Survey Subjects

Race/Ethnicity

79 (100)

9 (100)

70 (100)

 Black

13 (16.4)

2 (22.2)

11 (15.7)

 White

48 (60.8)

4 (44.4)

44 (62.9)

 Asian

14 (17.7)

2 (22.2)

12 (17.1)

 Pacific Islander/Other

4 (5.1)

0 (0)

4 (5.7)

 Mixed race

5 (6.3)

1 (11.1)

4 (5.7)

 Hispanic/LatinX

12 (15.2)

1 (11.1)

11 (15.7)

Gender

81 (100)

9 (100)

68 (100)

 Cis-Male

76 (93.8)

9 (100)

63 (92.6)

 Cis-Female

2 (2.4)

0 (0)

2 (2.9)

 Trans-male

1 (1.2)

0 (0)

1 (1.5)

 Non-binary

1 (1.2)

0 (0)

1 (1.5)

 Non-conforming

1 (1.2)

0 (0)

1 (1.5)

Age (years)

28 (24–40)

39 (29–59)

27 (23–36.5)

Occupation

77 (100)

9 (100)

68 (100)

 Healthcare worker

10 (13)

1 (11.1)

10 (14.7)

 Other at-risk occupation

6 (7.8)

0 (0)

6 (8.8)

Educational level

80 (100)

9 (100)

69 (100)

 Less than high school

0 (0)

0 (0)

0 (0)

 Completed high school

19 (23.8)

3 (33.3)

16 (23.2)

 College degree

22 (27.5)

1 (11.1)

22 (31.9)

 Post-graduate or other advanced degrees

36 (45)

5 (55.6)

30 (43.5)

Annual income

76 (100)

4 (100)

66 (100)

 $75 K or greater

23 (30.3)

3 (75)

21 (31.8)

 $40 K- $74 K

13 (17.1)

0 (0)

12 (18.2)

 $20 K- $39 K

20 (26.3)

0 (0)

15 (22.7)

  < $20 K

20 (26.3)

1 (25)

18 (27.3)

Medical Insurance

78 (100)

9 (100)

68 (100)

 Private Insurance

64 (82.1)

5 (55.6)

57 (83.8)

 Medicaid

7 (9)

2 (22.2)

5 (7.4)

 Medicare

7 (9)

0 (0)

6 (8.8)

 None

0 (0)

0 (0)

Behaviors

Gender of sex partners

81 (100)

9 (100)

69 (100)

 Male alone

69 (85.2)

8 (88.9)

58 (84.1)

 Female alone

1 (1.2)

0 (0)

1 (1.4)

 Both

11 (13.6)

1 (11.1)

10 (14.5)

Number of sexual partners

 Past 6 months

4 (3–10)

4 (2–10)

4 (3–10)

 Past 2 weeks

1 (1–2)

1 (1–1.5)

1 (1–2)

Intimate behaviors/sexual practices

79 (100)

9 (100)

69 (100)

 Hugging

70 (88.0)

5 (55.6)

64 (92.8)

 Kissing

72 (91.1)

5 (55.6)

65 (94.2)

 Oral intercourse

76 (96.2)

7 (77.8)

69 (100)

 Insertive anal intercourse

55 (69.6)

5 (55.6)

48 (69.5)

 Receptive anal intercourse

50 (63.3)

4 (44.4)

46 (66.7)

 Insertive vaginal intercourse

6 (7.6)

1 (11.1)

5 (7.2)

Condom Usage

90% (34.8–100%)

80% (25–100%)

90% (38.3–100%)

HIV Status

81 (100)

 Positive

11.50%

 Negative

84.80%

 Unknown

3.70%

STI history

81 (100)

9 (100)

69 (100)

 Ever

33 (40.7)

7 (77.8)

25 (36.2)

  Gonorrhea

17 (21)

5 (55.6)

12 (17.4)

  Chlamydia

15 (18.5)

2 (22.2)

12 (17.4)

  Syphilis

11 (13.6)

5 (55.56)

6 (8.7)

  HPV

8 (9.9)

1 (11.1)

7 (10.1)

  Genital herpes

1 (1.2)

1 (11.1)

0 (0)

 Past 6 months

10 (12.3)

2 (22.22)

8 (9.9)

  Gonorrhea

7 (8.6)

2 (22.2)

5 (6.2)

  Chlamydia

3 (3.7)

2 (22.2)

2 (2.5)

  Syphilis

2 (2.5)

1 (11.1)

2 (2.5)

  Trichomoniasis

1 (1.2)

0 (0)

1 (1.2)

  HPV

1 (1.2)

1 (11.1)

1 (1.2)

  M. genitalium

1 (1.2)

0 (0)

1 (1.2)

  Genital herpes

0 (0)

0 (0)

0 (0)

Substance use

77 (100)

9 (100)

67 (100)

 No

34 (44.2)

3 (33.3)

31 (46.3)

 Yes

43 (55.8)

6 (66.7)

36 (53.7)

  Marijuana

37 (48.1)

4 (44.4)

32 (47.8)

  Poppers or other inhalants

19 (24.7)

3 (33.3)

16 (23.9)

  Cocaine

14 (18.2)

2 (22.2)

12 (17.9)

  Ketamine

6 (7.8)

2 (22.2)

4 (6)

  Methamphetamine

5 (6.5)

3 (33.3)

2 (3)

  Mushrooms/psilocybin

3 (3.9)

0 (0)

3 (4.5)

  MDMA

1 (1.3)

0 (0)

1 (1.5)

  LSD

1 (1.3)

0 (0)

1 (1.5)

  PCP

1 (1.3)

0 (0)

1 (1.5)

  Heroin

1 (1.3)

0 (0)

1(1.5)

Tobacco

71 (100)

9 (100)

61 (100)

 Yes

13 (18.3)

3 (33.3)

10 (13.1)

 No

58 (81.7)

6 (66.7)

51 (86.9)

Alcohol

73 (100)

9 (100)

63 (100)

 Yes

64 (87.7)

7 (77.8)

56 (88.9)

  Moderate

64 (87.7)

7 (100)

56 (88.9)

  Heavy

0 (0)

0 (0)

0 (0)

 No

9 (12.3)

2 (22.2)

7 (11.1)

Behaviors

Aware of PrEP

79 (100)

9 (100)

69 (100)

 Yes

75 (94.9)

8 (88.9)

66 (95.7)

 No

4 (5.1)

1 (11.1)

3 (4.3)

Brand Awareness

65 (100)

2 (100)

63 (100)

 Tenofovir disoproxil fumarate/

43 (65.8)

2 (100)

41 (65.1)

  emtricitabine

29 (44.4)

2 (100)

27 (42.9)

 Tenofovir alafenamide/

4 (6.3)

0 (0)

4 (6.3)

  emtricitabine

 Cabotegravir

PrEP Usage

69 (100)

69 (100)

 Yes

33 (48.1)

33 (48.1)

 No

36 (51.9)

36 (51.9)

Brand Usage

33 (100)

33 (100)

 Tenofovir disoproxil fumarate/emtricitabine

21 (63.6)

21 (63.6)

 Tenofovir alafenamide/emtricitabine

11 (33.3)

11 (33.3)

 Cabotegravir

1 (3)

1 (3)

Prescription Provider

32 (100)

32 (100)

 Primary Care Provider

24 (75)

24 (75)

 HIV Specialist/Clinician

4 (12.5)

4 (12.5)

 Other sources

4 (12.5)

4 (12.5)

Adherence

28 (100)

28 (100)

 Full (no missed doses)

21 (75)

21 (75)

 At least 4 doses per week

2 (7)

2 (7)

 Less than 4 doses a week

5 (17.9)

5 (17.9)

Preferred Route of Administration

40 (100)

40 (100)

 Oral agent

30 (75.8)

30 (75.8)

 Injectable agent into muscle

5 (13)

5 (13)

 Injectable agent into skin

4 (10.1)

4 (10.1)

 Implant

1 (4.3)

1 (4.3)

Openness to Self-Injection

42 (100)

42 (100)

 Yes

18 (42.9)

18 (42.9)

 No

24 (57.1)

24 (57.1)

Preferred Frequency

44 (100)

44 (100)

 Daily

7 (15.9)

7 (15.9)

 Weekly

11 (25)

11 (25)

 Monthly

14 (31.8)

14 (31.8)

 Every 2 months

5 (11.2)

5 (11.2)

 Every 6 months

8 (18.4)

8 (18.4)

 1 year or more

17 (38.6)

17 (38.6)